Clinical trials: 5-FU, completed
Colorectal Cancer
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in…
- Trial name
- CanStem303C (NCT02753127)
- Testing
- Napabucasin, Fluorouracil, Leucovorin
- Where
- 211 sites in United States, Australia and 14 more
- Volunteers
- 1,253 people
- Sponsor
- Sumitomo Pharma America, Inc.
Breast Cancer
Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003730
- Testing
- fluorouracil, vinorelbine tartrate
- Where
- 17 sites in Belgium, France and 2 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colon Cancer
FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
This project consists of two independent, following specific eligibility criteria and different randomisation schemes studies, later on called DURATION study and BEV study.
- Trial name
- TOSCA (NCT00646607)
- Testing
- FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
- Where
- 111 sites in Italy
- Volunteers
- 3,756 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Colorectal Cancer
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Although treatment for metastatic colorectal cancer has improved significantly over the recent years, it still remains a significant health problem representing the leading cancer by incidence in the United States of America.
- Trial name
- NCT00199797
- Testing
- Oxaliplatin, 5-Fluorouracil, Leucovorin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Ludwig Institute for Cancer Research
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01985256
- Testing
- Toca 511, Toca FC
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tocagen Inc.
Metastatic Colorectal Cancer
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.
- Trial name
- AtezoTRIBE (NCT03721653)
- Testing
- Bevacizumab, Irinotecan, Oxaliplatin
- Where
- Italy
- Volunteers
- 218 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Breast Cancer
Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients
Radiation applied to the preserved breast during radiotherapy treatment activates numerous molecular cascades in tumor bed adjacent cells causing an inflammatory state.
- Trial name
- CCB-RT (NCT04002570)
- Testing
- blood samples collection
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Clinica Luganese Moncucco
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
This phase II trial studies how well combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy (SBRT) and nelfinavir mesylate works in treating patients with pancreatic cancer that has…
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01959672
- Testing
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Hepatocellular Carcinoma
Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma
This is a single-center, single-arm, open-label, prospective phase 2 trial to assess the efficacy of localized concurrent chemoradiation therapy (CCRT) and sorafenib sequential therapy in subjects with advanced HCC.
- Trial name
- NCT02425605
- Testing
- CCRT, sorafenib
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Colorectal Cancer
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00055822
- Testing
- oblimersen sodium, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Intrahepatic Cholangiocarcinoma
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is associated with poor prognosis. This study aims to explore the efficacy and safety FOLFOX-HAIC in combination with targeted therapy and/or PD-1 inhibitors for patients with initially…
- Trial name
- NCT05489692
- Testing
- hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
BRAF V600E-mutant Metastatic Colorectal Cancer
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in…
- Trial name
- BEACON CRC (NCT02928224)
- Testing
- Encorafenib, Binimetinib, Cetuximab
- Where
- 418 sites in United States, Argentina and 25 more
- Volunteers
- 702 people
- Sponsor
- Pfizer
Neuroendocrine Tumors
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced duodeno-pancreatic NETs, with a response rate of 30 to 40% and a…
- Trial name
- MGMT-NET (NCT03217097)
- Testing
- Oxaliplatin-based chemotherapy, Alkylating-based chemotherapy
- Where
- 19 sites in France
- Volunteers
- 116 people
- Sponsor
- Hospices Civils de Lyon
Metastatic Colorectal Cancer
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients
- Trial name
- NCT01437618
- Testing
- FOLFOXIRI plus bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Head and Neck Cancer
Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer
This multicenter, open-label, uncontrolled phase II trial evaluates safety and efficacy of post-operative chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck.
- Trial name
- ACCRA-HN (NCT00791141)
- Testing
- Cetuximab
- Where
- 10 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Nasopharyngeal Carcinoma
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
The aim of the study is to assess if gemcitabine in combination with carboplatin as 1st line chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma has reasonable efficacy and a favourable toxicity profile…
- Trial name
- NCT00697905
- Testing
- Gemcitabine, Carboplatin, Cisplatin
- Where
- 11 sites in Malaysia
- Volunteers
- 18 people
- Sponsor
- Ministry of Health, Malaysia
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
Pancreatic Cancer Non-resectable
Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
The aim of this study is to identify new prognostic factors in patients affected by advanced pancreatic carcinoma treated with first line chemotherapy with FOLFIRINOX regimen.
- Trial name
- HOPE (NCT03590275)
- Testing
- FOLFIRINOX
- Where
- 7 sites in Italy
- Volunteers
- 343 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Drug and/or Toxin-induced Diarrhea
Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
This is a randomized, stratified, double-blind, double-dummy, parallel group, placebo-controlled, dose finding, multicentre, multinational, phase II study in patient with colorectal cancer receiving 5- Fluorouracil (5-FU)-based…
- Trial name
- NCT02383810
- Testing
- Elsiglutide
- Where
- 54 sites in Belarus, Bulgaria and 6 more
- Volunteers
- 498 people
- Sponsor
- Helsinn Healthcare SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.